- Home
- ZS vs RPRX Comparison
ZS vs RPRX Comparison
Compare ZS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZS | RPRX |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 25.9B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZS | RPRX |
|---|---|---|
| Price | $184.44 | $59.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 38 | 5 |
| Target Price | ★ $264.94 | $51.40 |
| AVG Volume (30 Days) | 2.1M | ★ 2.8M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 30.77 | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $27.83 | $38.63 |
| Revenue Next Year | $19.67 | $4.73 |
| P/E Ratio | ★ N/A | $82.54 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $114.63 | $34.63 |
| 52 Week High | $336.99 | $60.44 |
Technical Indicators
Market Signals| Indicator | ZS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.46 | 57.96 |
| Support Level | $139.28 | $55.66 |
| Resistance Level | $191.25 | $60.44 |
| Average True Range (ATR) | 7.49 | 1.42 |
| MACD | 2.61 | -0.01 |
| Stochastic Oscillator | 87.23 | 69.85 |
Price Performance
Historical ComparisonAbout ZS Zscaler Inc.
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.